G2S2 CAPITAL INC. ANNOUNCES INCREASED INVESTMENT IN KNIGHT THERAPEUTICS INC.
HALIFAX, NS, Jan. 31, 2024 /CNW/ - G2S2 Capital Inc. ("G2S2") announces that its wholly owned subsidiary has acquired an additional 147,000 common shares of Knight Therapeutics Inc. ("Knight"), representing approximately 0.14% of the outstanding common shares of Knight. G2S2's wholly owned subsidiary, Armco Alberta Inc., acquired the common shares on January 31st, 2024, through the facilities of the Toronto Stock Exchange at a price of $5.35 per share (the "Acquisition").
Prior to the Acquisition, G2S2 beneficially owned and exercised control over an aggregate of 12,118,600 common shares of Knight, representing approximately 11.98% of the outstanding shares. Immediately after the Acquisition, G2S2 beneficially owns and exercises control over an aggregate of 12,265,600 common shares of Knight, representing approximately 12.12% of the outstanding shares.
The shares were acquired for investment purposes. G2S2 may, from time to time, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over common shares of Knight through market transactions, private agreements, or otherwise.
In accordance with National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, G2S2 has filed an early warning report regarding this transaction under Knight's profile on SEDAR+ (www.sedarplus.ca). Knight's head office is located at 3400 De Maisonneuve W., Suite 1055, Montreal, Quebec, H3Z 3B8.
About G2S2
G2S2 Capital Inc. is a privately held investment holding company focused on creating value across a variety of businesses with a long term horizon. G2S2 is incorporated under the laws of Canada. G2S2 is controlled
by George & Simé Armoyan.
For further information or to obtain a copy of the early warning report, please contact
George Armoyan, Executive Chairman of G2S2 at 416-855-1922.
SOURCE G2S2 Capital Inc.
View original content: http://www.newswire.ca/en/releases/archive/January2024/31/c4265.html
